Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

34.92USD
25 Sep 2017
Change (% chg)

$0.09 (+0.26%)
Prev Close
$34.83
Open
$34.60
Day's High
$35.31
Day's Low
$34.43
Volume
507,937
Avg. Vol
403,060
52-wk High
$41.69
52-wk Low
$23.07

Chart for

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $1,533.98
Shares Outstanding(Mil.): 44.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

Sep 20 2017

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

Sep 19 2017

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

Aug 03 2017

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

Aug 01 2017

BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept

* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma

Jun 12 2017

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

Jun 01 2017

BRIEF-Acceleron Pharma qtrly loss per share $0.66

* Acceleron pharma reports first quarter 2017 operational and financial results

May 08 2017

BRIEF-Acceleron announces management change

* Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer

May 02 2017

BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2

* Acceleron provides clinical development updates on luspatercept program

Apr 27 2017

Earnings vs. Estimates